Brokerages Anticipate Evofem Biosciences Inc (NASDAQ:EVFM) to Post -$0.29 EPS

Analysts expect Evofem Biosciences Inc (NASDAQ:EVFM) to post earnings of ($0.29) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Evofem Biosciences’ earnings, with estimates ranging from ($0.32) to ($0.28). Evofem Biosciences posted earnings of ($0.58) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 50%. The firm is scheduled to issue its next quarterly earnings results on Friday, March 6th.

According to Zacks, analysts expect that Evofem Biosciences will report full year earnings of ($2.15) per share for the current financial year, with EPS estimates ranging from ($2.25) to ($2.05). For the next financial year, analysts anticipate that the company will post earnings of ($1.30) per share, with EPS estimates ranging from ($1.76) to ($0.97). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Evofem Biosciences.

Evofem Biosciences (NASDAQ:EVFM) last released its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.30) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.01.

Several equities analysts recently commented on EVFM shares. HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Evofem Biosciences in a research note on Wednesday, November 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $9.00 price objective on shares of Evofem Biosciences in a research note on Wednesday, October 16th. ValuEngine downgraded shares of Evofem Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Finally, Zacks Investment Research upgraded shares of Evofem Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Evofem Biosciences has a consensus rating of “Hold” and an average target price of $8.75.

Shares of EVFM stock traded up $0.75 on Monday, hitting $6.86. The company’s stock had a trading volume of 927,704 shares, compared to its average volume of 64,278. The stock’s 50 day moving average is $5.39 and its 200-day moving average is $5.41. Evofem Biosciences has a fifty-two week low of $3.16 and a fifty-two week high of $7.50. The company has a market capitalization of $321.12 million, a PE ratio of -1.20 and a beta of 0.65.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In other Evofem Biosciences news, CEO Saundra L. Pelletier sold 10,000 shares of the stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $6.01, for a total transaction of $60,100.00. Following the sale, the chief executive officer now directly owns 424,676 shares in the company, valued at $2,552,302.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 13.40% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Strs Ohio acquired a new stake in Evofem Biosciences during the second quarter worth about $25,000. Millennium Management LLC acquired a new stake in Evofem Biosciences during the third quarter worth about $79,000. King Luther Capital Management Corp acquired a new stake in Evofem Biosciences during the second quarter worth about $100,000. Susquehanna International Group LLP acquired a new stake in Evofem Biosciences during the second quarter worth about $149,000. Finally, JPMorgan Chase & Co. acquired a new stake in Evofem Biosciences during the second quarter worth about $163,000. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Evofem Biosciences Company Profile

Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women.

Read More: What is a Fibonacci Channel?

Get a free copy of the Zacks research report on Evofem Biosciences (EVFM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evofem Biosciences (NASDAQ:EVFM)

Leave a Reply

Your email address will not be published. Required fields are marked *

*